Grifols (GIFLF) Equity Income (2010 - 2023)
Grifols' (GIFLF) quarterly Equity Income came in at -$1075.9 in Q4 2023, up 99.98% quarter-over-quarter from -$6.0 million in Q1 2020.
Analysis
Grifols (GIFLF) Equity Income (2010 - 2023) Analysis & Trends
Grifols (GIFLF) has reported Equity Income for 11 consecutive years, with -$1075.9 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Equity Income changed N/A year-over-year to -$1075.9; the trailing twelve-month figure through Dec 2023 stood at -$56.6 million (changed N/A YoY), and the FY2023 full-year result was -$1.1 million, up 28.84% from the prior year.
- Equity Income improved to -$1075.9 in Q4 2023 per GIFLF's latest filing, from -$6.0 million in the prior quarter.
- Across five years, Equity Income topped out at -$1075.9 in Q4 2023 and bottomed at -$43.8 million in Q4 2019.
- Historically, Equity Income has averaged -$14.2 million across 3 years, with a median of -$6.4 million in 2019.
- The sharpest annual moves came in 2019 and 2020: Equity Income tumbled 247.37% in 2019, then rose 11.9% in 2020.
- Over 3 years, Equity Income stood at -$43.8 million in 2019, then surged by 86.25% to -$6.0 million in 2020, then soared by 99.98% to -$1075.9 in 2023.
- According to Business Quant data, Equity Income over the past three periods registered -$1075.9, -$6.0 million, and -$43.8 million for Q4 2023, Q1 2020, and Q4 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -1,075.94 |
| Mar 31, 2020 | -6.02 Mn |
| Dec 31, 2019 | -43.76 Mn |
| Mar 31, 2019 | -6.83 Mn |
| Dec 31, 2018 | -12.60 Mn |
| Mar 31, 2018 | -2.53 Mn |
| Dec 31, 2017 | -23.42 Mn |
| Mar 31, 2017 | -3.50 Mn |
| Dec 31, 2015 | -5.13 Mn |
| Sep 30, 2015 | 2.47 Mn |
| Jun 30, 2015 | 1,180.29 |
| Mar 31, 2015 | -355,897.24 |
| Dec 31, 2014 | 4.56 Mn |
| Sep 30, 2014 | 674,264.05 |
| Jun 30, 2014 | 2,555.80 |
| Mar 31, 2014 | 2.17 Mn |
| Dec 31, 2013 | -593,435.05 |
| Sep 30, 2013 | -381,611.12 |
| Jun 30, 2013 | 1.36 Mn |
| Mar 31, 2013 | 356,495.00 |